Why CorMedix Could See 300% Upside From the Defencath Central Venous Catheter24/7 Wall Street • 09/21/20
CorMedix Inc. Announces FDA Acceptance for Filing and Priority Review of New Drug Application for DefencathGlobeNewsWire • 08/31/20
CorMedix's (CRMD) CEO Khoso Baluch on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/11/20
CorMedix Inc. Reports Second Quarter and Six Month 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 08/10/20
CorMedix Inc. to Report Second Quarter 2020 Financial Results and Provide a Corporate Update on August 10GlobeNewsWire • 08/03/20
CorMedix, Inc. (CRMD) CEO Khoso Baluch on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/12/20
CorMedix Inc. Announces Contract Extension of Jack Armstrong as Executive Vice President and Head of Technical OperationsGlobeNewsWire • 04/23/20
CorMedix Completes Sale of $5.5 Million of NOL Tax Benefits through New Jersey Technology Business Tax Certificate Transfer ProgramGlobeNewsWire • 04/22/20
CorMedix, Inc. (CRMD) CEO Khoso Baluch on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/17/20
CorMedix Approved to Sell $5.5 Million of NOL Tax Benefits Through the New Jersey Economic Development Authority ProgramGlobeNewsWire • 02/03/20